SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing sovereign-AI demand and growth in customized software, is reinforcing Palantirs AI growth story as the stock reaches fresh highs. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics warn that the valuation is stretched and the rally could pull back.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are largely bullish on the technology and momentum, while some remain wary of token unlocks and selling pressure.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising fears that it could eventually compete with established wireless carriers. Traders are divided between seeing a lasting competitive threat and viewing the reaction as excessive, arguing that building a capable terrestrial network would take substantial time and investment.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff and underperformance versus U.S. airline peers are driving discussion, with traders citing oil and fuel-cost uncertainty and speculating about shorting or selling pressure after the share bid. Bears see further downside, while bulls point to buybacks and Aeroplans value as reasons for optimism.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is drawing attention for choppy, range-bound trading, with repeated failures to clear the psychologically important 10-cent level fueling frustration. Bulls are calling the pullbacks accumulation opportunities and anticipating a breakout alongside a broader crypto rally, while bears see the stalled price action as a sign of further weakness.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

A report of a planned NIH-backed push to accelerate personalized cancer vaccines has lifted vaccine stocks, including BioNTech. Traders are discussing the sector rally and BioNTechs oncology pipeline, while some question why BNTX is lagging Moderna.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is drawing attention after its and Modernas personalized cancer vaccine with Keytruda met key endpoints in a Phase 3 melanoma trial, renewing interest in the companies oncology pipeline. Traders see potential beyond melanoma and a boost to Mercks growth outlook, while others caution that full results, overall-survival data, and broader commercial potential remain uncertain.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds recent pullback and tentative rebound are driving discussion, with traders weighing whether support marks a bottom or whether a stronger dollar, elevated yields and hawkish Fed expectations could extend the decline. Some see dip-buying and central-bank demand as supportive, while others remain cautious pending confirmation.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets push to fresh highs is drawing attention amid strength across cybersecurity stocks and optimism that AI-related security risks will support demand. Traders are split between momentum continuing and concern that stretched valuations and light trading volume leave the rally vulnerable to a pullback.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers sharp selloff and persistent underperformance versus other space stocks dominate the discussion, with traders blaming financing and potential dilution concerns around a convertible-note offering. Bearish frustration over management and cash use contrasts with some traders viewing the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Pharma Limited

$OKYO reported first patient enrollment in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain.

Feed

News

Sentiment

Fundamentals

Info

OKYO Pharma Limited

Fundamentals

Latest OKYO News